3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate,
BMS 477118,
BMS-477118,
BMS477118,
Onglyza,
saxagliptin,
Saxagliptin,
Onglyza,
361442-04-8,
BMS-477118,
OPC-262,
UNII-8I7IO46IVQ,
BMS 477118,
Saxagliptin [INN],
8I7IO46IVQ,
CHEMBL385517,
CHEBI:71272,
Saxagliptin (INN),
BMS-477118-11,
(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile,
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
BMS477118,
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
Saxagliptine,
Saxagliptin (BMS-477118,Onglyza),
HSDB 8199,
OPC 262,
NCGC00242597-01,
Saxagliptin anhydrous,
Saxagliptin(Onglyza),
DSSTox_CID_28506,
DSSTox_RID_82778,
DSSTox_GSID_48580,
SCHEMBL17168,
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-,
cc-226,
MLS006011223,
GTPL6316,
Saxagliptin - BMS-477118,
DTXSID7048580,
SCHEMBL20243458,
BDBM11542,
QGJUIPDUBHWZPV-SGTAVMJGSA-N,
HMS3264P11,
Pharmakon1600-01502500,
Tox21_112908,
BDBM50225074,
NSC760407,
s1540,
AKOS015896547,
AC-6008,
AN-5808,
CCG-213084,
DB06335,
EX-7795,
NSC-760407,
NCGC00242597-02,
SMR004702984,
AB1008460,
AM20090693,
CAS-361442-04-8,
D08996,
Q-4418,
AB01562984_01,
AB01562984_02,
I06-2477,
BRD-A81513827-001-03-6,
Z2235802036,
(S)-3-Hydroxyadamantylglycine-L-cis-4,5-methanoprolinenitrile TFA salt,
(1S,6S)-2-(2-adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid,
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
(1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; Onglyza,
(1S,3S,5S)-2-[(S)-2-amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,
(1s,3s,5s)-2-[2(s)-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
(1S,3S,5S)-4-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-4-azabicyclo[3.1.0]hexane-3-carbonitrile,
2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl) , (1S,3S,5S)-,
Saxagliptin HCl,
Saxagliptin hydrate,
Onglyza (TN),
Saxagliptin [USAN],
Kombiglyze XR (TN),
Saxagliptin hydrochloride,
D0K9MY,
UNII-9GB927LAJW,
Saxagliptin [USAN:INN:BAN],
ACN-031557,
CID11243969,
BMS 477118-11,
C502994,
3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate,
(S)-3-hydroxyadamantylglycine-L-cis-4,5-methanoprolinenitrile,
(1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
945667-22-1,
Saxagliptin, 97%, selective and reversible DPP4 inhibitor - 10MG 10mg,
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3,
(1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl) acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile hydrate,